Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back
05 Apr 2024
Outside biotech money isn’t pouring into China like it used to.
In 2020 and 2021, venture investors put nearly $8 billion into Chinese biopharmas. But in the years that followed, those amounts have plunged as investors have sharply pulled back from China, according to data from DealForma. Private investments last year totaled a mere $600 million. And the decline has been echoed in the public market as well: A November report from McKinsey suggests that among 35 listed China biotechs, $80 billion in market cap had been erased since the peak.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.